Aurase Wound Gel shows 22x faster debridement and 7x faster healing compared to standard of care in sloughy venous leg ulcers, supporting advancement to the next phase of development
SolasCure Ltd has reported positive results from its second Phase II clinical study, CLEANVLU2, evaluating Aurase Wound Gel for the treatment of chronic wounds. The company stated that the investigational therapy demonstrated faster healing compared with current standard care, reinforcing its potential to provide ongoing enzymatic debridement while also stimulating the body’s natural repair processes. The announcement marks an important development step for SolasCure as it advances a new approach to chronic wound management.
Health Technology Insights: Ambience Healthcare Teams With MultiCare on AI Platform Rollout
Aurase Wound Gel combines a proprietary hydrogel base with tarumase, the active pharmaceutical ingredient designed to break down necrotic tissue. The earlier Phase IIa CLEANVLU1 study established proof of concept, showing favorable safety results and a pain free application experience. The CLEANVLU2 trial expanded on those findings by assessing dose response and therapeutic impact in patients with difficult to treat venous leg ulcers. According to the company, higher concentrations of tarumase delivered notably stronger clinical outcomes. Data from the study showed that sloughy wounds were debrided significantly faster than with standard care, and overall healing progressed at a markedly improved rate. By day 26, patients treated with Aurase achieved substantially greater debridement and wound area reduction compared with the control group, with statistically meaningful differences between the two arms.
Health Technology Insights: Lōkahi Therapeutics Welcomes UGA Fellows to ai² Futures Lab
Researchers observed that the therapy appears to work through a dual mechanism. In addition to removing nonviable tissue on a continuous basis, tarumase is believed to activate PAR2 receptors that play a role in tissue repair, helping to initiate healing pathways early in treatment. Throughout the trial, Aurase maintained a strong safety profile and did not increase pain for participants. Patients also reported improvements in aspects of daily life, including physical comfort and overall wellbeing.
Chronic wounds represent a persistent challenge for healthcare systems worldwide, affecting millions of individuals and driving significant treatment costs. Many existing therapies focus primarily on preparing the wound bed rather than directly encouraging biological healing. SolasCure believes the results from CLEANVLU2 support the potential of Aurase to address debridement and sustained healing within a single therapy. The company views these findings as an important milestone as it continues product development and engages with investors and strategic partners to bring the treatment closer to market.
Health Technology Insights: Oncotype DX Breast Test Exceeds 2 Million Patients Globally
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
